BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Director of Communications and Investor Relations Presents at LD Micro Main Event
BiondVax summarizes collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to discover and develop nanosized antibody (NanoAb) therapies that address underserved and growing markets, including COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration. The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during the forecast period, resulting in a value of $35.42 billion by 2025 The psoriasis market is experiencing a higher-than-expected demand across all regions due to the increasing geriatric population and the growing prevalence of plaque…